Shima J, Yoshioka T, Kosugi A, Ogata M, Fujiwara H, Hamaoka T, Ueda S, Kato S
Department of Oncogenesis, Osaka University Medical School, Japan.
Biken J. 1987 Mar;30(1):1-8.
The role of the tumor-unique determinant(s) on two syngeneic murine hepatoma cells in inducing in vivo protective immunity was investigated in comparison with that of the tumor-cross-reactive determinant(s). Induction of vaccinia-reactive helper T cells in C3H/He mice by intraperitoneal (i.p.) inoculation of viable vaccinia virus and then immunization with vaccinia-infected syngeneic MH134 or MH129 tumor cells resulted in the production of potent anti-MH134 or -MH129 antibody as well as the generation of in vivo protective immunity. Neither antibody reacted with other syngeneic plasmacytoma or fibrosarcoma cells, but both cross-reacted appreciably with the other hepatoma cells as well reacted strongly as with the tumor cells used for immunization. The absorptions of anti-MH134 and -MH129 antisera with the respective hepatoma cells abolished their reactivities with both the corresponding hepatoma cells and the other hepatoma cells. In contrast, the absorption of these antisera with the other tumor cells resulted in loss of their cross-reactivities with the other hepatoma cells, but not loss of their specific reactivity to the respective hepatoma cells. Although in these hematoma systems, the above-mentioned immunization protocol resulted in in vivo induction of protective immunity and generation of antibodies, in vivo immunity as observed by Winn assays was mediated by Lyt-1+2- T cells and was specific for each type of hepatoma cells. These results indicate that these two types of hepatoma cells bear two kinds of antigenic determinants, one kind unique to each hepatoma and the other kind cross-reactive with the other hepatoma cells.(ABSTRACT TRUNCATED AT 250 WORDS)
研究了两种同基因小鼠肝癌细胞上肿瘤特异性决定簇在诱导体内保护性免疫中的作用,并与肿瘤交叉反应决定簇的作用进行了比较。通过腹腔内(i.p.)接种活痘苗病毒,然后用痘苗感染的同基因MH134或MH129肿瘤细胞免疫C3H/He小鼠,诱导痘苗反应性辅助性T细胞,可产生强效的抗MH134或-MH129抗体,并产生体内保护性免疫。两种抗体均不与其他同基因浆细胞瘤或纤维肉瘤细胞反应,但均与其他肝癌细胞有明显交叉反应,且与用于免疫的肿瘤细胞反应强烈。用相应肝癌细胞吸收抗MH134和-MH129抗血清后,它们与相应肝癌细胞和其他肝癌细胞的反应性均消失。相反,用其他肿瘤细胞吸收这些抗血清后,它们与其他肝癌细胞的交叉反应性丧失,但对各自肝癌细胞的特异性反应性未丧失。尽管在这些肝癌系统中,上述免疫方案可在体内诱导保护性免疫并产生抗体,但通过Winn试验观察到的体内免疫是由Lyt-1+₂⁻T细胞介导的,且对每种类型的肝癌细胞具有特异性。这些结果表明,这两种类型的肝癌细胞带有两种抗原决定簇,一种是每种肝癌特有的,另一种与其他肝癌细胞交叉反应。(摘要截短于250字)